Abstract
Brucellosis is a globally distributed zoonotic disease that causes animal and human diseases. However, the current Brucella abortus vaccines (S19 and RB51) are deficient; they can cause abortion in pregnant animals. Moreover, when the vaccine S19 is used, tests cannot differentiate natural from vaccinated infection. Therefore, a safer and more potent vaccine is needed. A Brucella abortus 2308 ery promoter mutant (Δery) was constructed to overcome these drawbacks. The growth of the Δery mutant was significantly attenuated in macrophages and mice and induced high protective immunity in mice. Moreover, Δery induced an anti-Brucella-specific IgG (immunoglobulin G) response and stimulated the expression of interferon-gamma (INF-γ) and interleukin-4 (IL-4). Furthermore, the expression of EryA antigen allowed for the serological differentiation between natural and vaccinated infection in mice. These results indicate that the Δery mutant is a potential attenuated live vaccine candidate against virulent Brucella abortus 2308 (S2308) infection.
Similar content being viewed by others
References
Adone, R., Ciuchini, F., Marianelli, C., Tarantino, M., Pistoia, C., Marcon, G., Petrucci, P., Francia, M., Riccardi, G., and Pasquali, P. 2005. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect. Immun. 73, 4198–4312.
Anderson, J.D. and Smith, H. 1965. The metabolism of erythritol in Brucella abortus. J. Gen. Microbiol. 38, 109–124.
Ashford, D.A., di Pietra, J., Lingappa, J., Woods, C., Noll, H., Neville, B., Weyant, R., Bragg, S.L., Spiegel, R.A., Tappero, J., and Perkins, B.A. 2004. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine 22, 3435–3439.
Berkelman, R.L. 2003. Human illness associated with use of veterinary vaccines. Clin. Infect. Dis. 37, 407–414.
Burkhardt, S., Jiménez de Bagüés, M.P., Liautard, J.P., and Köhler, S. 2005. Analysis of the behavior of eryC mutants of Brucella suis attenuated in macrophages. Infect. Immun. 73, 6782–6872.
Carvalho, L.H., Sano, G., Hafalla, J.C., Morrot, A., Curotto de Lafaille, M.A., and Zavala, F. 2002. IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat. Med. 8, 166–170.
Castaño, M.J. and Solera, J. 2009. Chronic brucellosis and persistence of Brucella melitensis DNA. J. Clin. Microbiol. 7, 2084–2089.
Cheville, N.F., Olsen, S.C., Jensen, A.E., Stevens, M.G., Palmer, M.V., and Florance, A.M. 1996. Effects of age at vaccination on efficacy of Brucella abortus strain RB51 to protect cattle against brucellosis. Am., J. Vet. Res. 57, 1153–1159.
Crasta, O.R., Folkerts, O., Fei, Z., Mane, S.P., Evans, C., Martino-Catt, S., Bricker, B., Yu, G., Du, L., and Sobral, B.W. 2008. Genome sequence of Brucella abortus vaccine strain S19 compared to virulent strains yields candidate virulence genes. PLoS ONE 3, e2193.
Delrue, R.M., Lestrate, P., Tibor, A., Letesson, J.J., and De Bolle, X. 2004. Brucella pathogenesis, genes identified from random largescale screens. FEMS Microbiol. Lett. 231, 1–12.
Elzer, P.H., Enright, F.M., Colby, L., Hagius, S.D., Walker, J.V., Fatemi, M.B., Kopec, J.D., Beal, V.C.Jr., and Schurig, G.G. 1998. Protection against infection and abortion induced by virulent challenge exposure after oral vaccination of cattle with Brucella abortus strain RB51. Am. J. Vet. Res. 59, 1575–1583.
Elzer, P.H., Hagius, S.D., Davis, D.S., DelVecchio, V.G., and Enright, F.M. 2002. Characterization of the caprine model for ruminant brucellosis. Vet. Microbiol. 90, 425–431.
Eoh, H., Jeon, B.Y., Kim, Z., Kim, S.C., and Cho, S.N. 2010. Expression and validation of D-erythrulose 1-phosphate dehydrogenase from Brucella abortus: a diagnostic reagent for bovine brucellosis. J. Vet. Diagn. Invest. 22, 524–554.
Ficht, T.A. 2003. Intracellular survival of Brucella: defining the link with persistence. Vet. Microbiol. 92, 213–223.
Godfroid, J., Cloeckaert, A., Liautard, J.P., Kohler, S., Fretin, D., Walravens, K., Garin-Bastuji, B., and Letesson, J.J. 2005. From the discovery of the Malta fever’s agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a reemerging zoonosis. Vet. Res. 36, 313–326.
Goel, D. and Bhatnagar, R. 2012. Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544. Mol. Immunol. 51, 159–168.
Golding, B., Scott, D.E., Scharf, O., Huang, L.Y., Zaitseva, M., Lapham, C., Eller, N., and Golding, H. 2001. Immunity and protection against Brucella abortus. Microbes Infect. 3, 43–48.
Hamdy, M.E., El-Gibaly, S.M., and Montasser, A.M. 2002. Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev.1 vaccines and challenged with Brucella melitensis bv. 3. Vet. Microbiol. 88, 85–94.
Lacerda, T.L., Cardoso, P.G., Augusto de Almeida, L., Camargo, I.L., Afonso, D.A., Trant, C.C., Macedo, G.C., Campos, E., Cravero, S.L, Salcedo, S.P., and et al. 2010. Inactivation of formyltransferase (wbkC) gene generates a Brucella abortus rough strain that is attenuated in macrophages and in mice. Vaccine 28, 5627–5634.
Liu, B., Teng, D., Wang, X., Yang, Y., and Wang, J. 2012. Expression of the soybean allergenic protein P34 in Escherichia coli and its indirect ELISA detection method. Appl. Microbiol. Biotechnol. 94, 1337–1382.
Meyer, M.E. 1967. Metabolic characterization of the genus Brucella. VI. Growth stimulation by i-erythritol compared with strain virulence for guinea pigs. J. Bacteriol. 93, 996–1000.
Moriyón, I., Grilló, M.J., Monreal, D., González, D., Marín, C., López-Goñi, I., Mainar-Jaime, R.C., Moreno, E., and Blasco, J.M. 2004. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet. Res. 35, 1–38.
Nicoletti, P. 1990. Vaccination against Brucella. Adv. Biotechnol. Processes 13, 147–215.
Olsen, S.C., Bricker, B., Palmer, M.V., Jensen, A.E., and Cheville, N.F. 1999. Responses of cattle to two dosages of Brucella abortus strain RB51: serology, clearance and efficacy. Res. Vet. Sci. 66, 101–106.
Poester, F.P., Gonçalves, V.S., Paixão, T.A., Santos, R.L., Olsen, S.C., Schurig, G.G., and Lage, A.P. 2006. Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. Vaccine 24, 5327–5361.
Sangari, F.J., Aguero, J., and Garcia-Lobo, J.M. 2000. The genes for erythritol catabolism are organized as an inducible operon in Brucella abortus. Microbiology 146, 487–495.
Sangari, F.J., Grilló, M.J., Jiménez De Bagüés, M.P., González-Carreró, M.I., García-Lobo, J.M., Blasco, J.M., and Agüero, J. 1998. The defect in the metabolism of erythritol of the Brucella abortus B19 vaccine strain is unrelated with its attenuated virulence in mice. Vaccine 16, 1640–1645.
Sathiyaseelan, J., Goenka, R., Parent, M., Benson, R.M., Murphy, E.A., Fernandes, D.M., Foulkes, A.S., and Baldwin, C.L. 2006. Treatment of Brucella susceptible mice with IL-12 increases primary and secondary immunity. Cell. Immunol. 243, 1–9.
Schurig, G.G., Roop, R.M., Bagchi, T., Boyle, S., Buhrman, D., and Sriranganathan, N. 1991. Biological properties of RB51 a stable rough strain of Brucella abortus. Vet. Microbiol. 28, 171–259.
Schurig, G.G., Sriranganathan, N., and Corbel, M.J. 2002. Brucellosis vaccines: past, present and future. Vet. Microbiol. 90, 479–496.
Sperry, J.F. and Robertson, D.C. 1975. Inhibition of growth by erythritol catabolism in Brucella abortus. J. Bacteriol. 124, 391–397.
Wang, Y., Bai, Y., Qu, Q., Xu, J., Chen, Y., Zhong, Z., Qiu, Y., Wang, T., Du, X., Wang, Z., and et al. 2011. The 16M ΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. Vet. Microbiol. 151, 354–362.
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to the work.
Rights and permissions
About this article
Cite this article
Zhang, J., Yin, S., Guo, F. et al. A potent Brucella abortus 2308 Δery live vaccine allows for the differentiation between natural and vaccinated infection. J Microbiol. 52, 681–688 (2014). https://doi.org/10.1007/s12275-014-3689-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-014-3689-9